<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809052</url>
  </required_header>
  <id_info>
    <org_study_id>GB1211-001</org_study_id>
    <secondary_id>2018-003914-41</secondary_id>
    <secondary_id>Covance Study Number: 8392356</secondary_id>
    <nct_id>NCT03809052</nct_id>
  </id_info>
  <brief_title>A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects</brief_title>
  <official_title>GB1211 - A Randomised, Double-Blind, Placebo-Controlled, First-In-Human, Study of Orally Administered GB1211 to Evaluate the Safety, Tolerability, and PK of Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galecto Biotech AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galecto Biotech AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in&#xD;
      which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be&#xD;
      evaluated in healthy adult subjects and adult subjects with indication of suspected&#xD;
      Nonalcoholic steatohepatitis (NASH) and liver fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of 2 parts: a SAD phase (Part A) which enrolled a total of 5 cohorts of&#xD;
      healthy subjects and a MAD phase (Part B) which enrolled 2 cohorts of healthy subjects. Two&#xD;
      additional cohorts A6 and A7, were added following dose escalation analysis.&#xD;
&#xD;
      The planned optional Part C was to include a multiple-dose cohort of 25 subjects with&#xD;
      suspected NASH and liver fibrosis (Cohort C1). However, Part C of the study was not performed&#xD;
      as per Sponsor's decision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A: 56 subjects will be studied in 7 cohorts (Cohorts A1 to A7) Part B: 22 subjects will be studied in 2 cohorts (Cohorts B1 to B2)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With of Adverse Events (AEs)</measure>
    <time_frame>Up to 5-7 days post final dose (Part A: Single dose), Part B: 6-7 weeks</time_frame>
    <description>The number of participants in each arm that report Adverse Events (AEs)</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Safety and Tolerability</condition>
  <arm_group>
    <arm_group_label>A1 - 5 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 - 20 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4 - 100 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A5 - 200 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 - GB1211 multiple ascending doses, 50mg BID and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 - GB1211 multiple ascending doses, 100mg BID and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A6 - 50mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A7 - 400 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Placebo for GB1211</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A - 2 subjects from each arm (A1-A5) will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Placebo for GB1211 (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B - 3 subjects from each arm B1 and B2 will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB1211</intervention_name>
    <description>Hard capsules for oral use</description>
    <arm_group_label>A1 - 5 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_label>A2 - 20 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_label>A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo</arm_group_label>
    <arm_group_label>A4 - 100 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_label>A5 - 200 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_label>A6 - 50mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_label>A7 - 400 mg GB1211 single dose and Placebo</arm_group_label>
    <arm_group_label>B1 - GB1211 multiple ascending doses, 50mg BID and Placebo</arm_group_label>
    <arm_group_label>B2 - GB1211 multiple ascending doses, 100mg BID and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Hard capsules for oral use</description>
    <arm_group_label>Part A - Placebo for GB1211</arm_group_label>
    <arm_group_label>Part B - Placebo for GB1211 (BID)</arm_group_label>
    <other_name>GB1211</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects for Parts A and B must satisfy all of the following criteria at the Screening&#xD;
        visit unless otherwise stated:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 55 years of age (60 years for Part B),&#xD;
             inclusive.&#xD;
&#xD;
          2. Body mass index (BMI) of 18.0 to 32.0 kg/m^2 (inclusive) with a minimum body weight of&#xD;
             50 kg.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory&#xD;
             evaluations&#xD;
&#xD;
          4. Females will not be pregnant or lactating, and females of childbearing potential and&#xD;
             males will agree to use contraception as detailed further in the protocol.&#xD;
&#xD;
          5. Male subjects must agree to refrain from sperm donation and females should refrain&#xD;
             from ova donation from the date of Check-in (Day -1) until 90 days after the Follow-up&#xD;
             visit.&#xD;
&#xD;
          6. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Subjects for Parts C must satisfy all of the following criteria at the Screening visit&#xD;
        unless otherwise stated:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 60 years of age, inclusive.&#xD;
&#xD;
          2. Body mass index (BMI) of ≥ 25.0 and ≤ 38.0 kg/m^2.&#xD;
&#xD;
          3. Documented history of fatty liver within the last 24 weeks by one of the following:&#xD;
             magnetic resonance imaging (MRI) suggesting liver fat ≥ 8%, ultrasound (US) indicating&#xD;
             fatty liver, or Fibroscan Controlled Attenuation Parameter (CAP) &gt; 270 dB/m. In&#xD;
             subjects without a documented history of fatty liver, a Fibroscan CAP or US can be&#xD;
             performed at Screening. Subjects with Fibroscan CAP &gt; 270 dB/m or US indicating fatty&#xD;
             liver are eligible.&#xD;
&#xD;
          4. Metabolic syndrome (Adult Treatment Panel III definition) or T2DM (defined as stable&#xD;
             diabetes with glycosylated haemoglobin [HbA1c] ≤ 9.5%).&#xD;
&#xD;
          5. Alanine aminotransferase (ALT) ≥ 20 U/L for females and ≥ 30 U/L for males at&#xD;
             Screening.&#xD;
&#xD;
          6. Fibroscan ≥ 7 KPa and &lt; 13 KPa, or Fibrosis-4 (FIB-4) index ≥ 1.1 and &lt;3.25.&#xD;
&#xD;
          7. Females of nonchildbearing potential defined as permanently sterile (ie, due to&#xD;
             hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy) or&#xD;
             postmenopausal (defined as at least 12 months postcessation of menses without an&#xD;
             alternative medical cause and follicle-stimulating hormone [FSH] level ≥ 40 mIU/mL).&#xD;
             Males will agree to use contraception as detailed in protocol.&#xD;
&#xD;
          8. Male subjects must agree to refrain from sperm donation and females should refrain&#xD;
             from ova donation from the date of Check-in (Day -1) until 90 days after the Follow-up&#xD;
             visit.&#xD;
&#xD;
          9. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects from Part A &amp; B will be excluded from the study if they satisfy any of the&#xD;
        following criteria at the Screening visit unless otherwise stated:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee).&#xD;
&#xD;
          2. History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             subjects with evidence of active infection.&#xD;
&#xD;
        3 (Part A). Any of the following: a. QTcF &gt; 450 msec confirmed by repeat measurement. b.&#xD;
        QRS duration &gt; 110 msec confirmed by repeat measurement. c. PR interval &gt; 220 msec&#xD;
        confirmed by repeat measurement. d. findings which would make QTc measurements difficult or&#xD;
        QTc data uninterpretable. e. history of additional risk factors for torsades de pointes&#xD;
        (eg, heart failure, hypokalaemia, family history of long QT syndrome).&#xD;
&#xD;
        3 (Part B). Clinically significant ECG abnormalities or QTcF greater than 450 msec for&#xD;
        males and 470 msec for females at either Screening or Day 1 predose, or any prior history&#xD;
        of QT abnormality.&#xD;
&#xD;
        4. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in.&#xD;
&#xD;
        5. Positive hepatitis panel and/or positive human immunodeficiency virus (HIV) test.&#xD;
&#xD;
        6. Participation in a clinical study involving administration of an investigational agent&#xD;
        or vaccine (new chemical entity) or having received a biological product in the past 90&#xD;
        days prior to dosing.&#xD;
&#xD;
        7. Use or intend to use any medications/products known to alter drug absorption,&#xD;
        metabolism, or elimination processes, including St. John's wort, within 30 days prior to&#xD;
        dosing, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
        8. Use or intend to use any prescription medications/products other than hormone&#xD;
        replacement therapy, oral, implantable, transdermal, injectable, or intrauterine&#xD;
        contraceptives within 14 days prior to dosing, unless deemed acceptable by the Investigator&#xD;
        (or designee).&#xD;
&#xD;
        9. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in, or&#xD;
        positive cotinine at Screening or Check-in.&#xD;
&#xD;
        10. Receipt of blood products within 2 months prior to Check-in and donation of blood from&#xD;
        3 months prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6&#xD;
        weeks prior to Screening.&#xD;
&#xD;
        11. Subject who, in the opinion of the Investigator (or designee), should not participate&#xD;
        in this study.&#xD;
&#xD;
        Subjects from Part C will be excluded from the study if they satisfy any of the following&#xD;
        criteria at the Screening visit unless otherwise stated:&#xD;
&#xD;
          1. If diabetic and diabetes is other than T2DM.&#xD;
&#xD;
          2. Subjects, who have had bariatric surgery of any kind or, in the opinion of the&#xD;
             Investigator, have experienced a clinically significant change in body weight within&#xD;
             the 3 months prior to Screening.&#xD;
&#xD;
          3. History of any known serious disease (such as cancer, except skin basocellular&#xD;
             carcinomas, major infection, clinically significant gastrointestinal disorder, major&#xD;
             autoimmune disease) or other disease which in the Investigator's opinion would exclude&#xD;
             the patient from the study.&#xD;
&#xD;
          4. The following clinical laboratory results at Screening: -Total Bilirubin &gt; 2 × ULN,&#xD;
             ALT &gt; 155 U/L for females and &gt; 185 U/L for males, AST &gt; 155 U/L for females and &gt; 200&#xD;
             U/L for males&#xD;
&#xD;
          5. Other abnormal clinical laboratory values that are considered clinically significant&#xD;
             for this population.&#xD;
&#xD;
          6. Clinically significant ECG abnormalities or QTcF greater than 450 msec for males and&#xD;
             470 msec for females at either Screening or Day 1 predose, or any prior history of QT&#xD;
             abnormality.&#xD;
&#xD;
          7. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in.&#xD;
&#xD;
          8. Alcohol consumption of &gt; 14 units per week for males and for females. One unit of&#xD;
             alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill&#xD;
             (25 mL) of spirits.&#xD;
&#xD;
          9. Positive alcohol breath test result or positive urine drug screen (confirmed by&#xD;
             repeat) at Screening or Check-in.&#xD;
&#xD;
         10. Positive hepatitis panel and/or positive HIV test .&#xD;
&#xD;
         11. A creatinine clearance of less than 50 mL/min (as calculated by Cockcroft-Gault&#xD;
             equation) or estimated glomerular filtration rate (eGFR) &lt; 60 mL/[min*1.73 m²] at&#xD;
             Screening.&#xD;
&#xD;
         12. Subject taking any antidiabetic medications, with the exception of metformin,&#xD;
             sulfonylureas, gliptins, and sodium/glucose co-transporter 2 inhibitors, within 3&#xD;
             months prior to Screening.&#xD;
&#xD;
         13. Use of any of the following non-permitted medication within 6 months prior to&#xD;
             Screening: amiodarone, bile salt chelators, methotrexate, pharmacological doses of&#xD;
             systemic corticosteroids for at least 2 consecutive weeks, or any other medications&#xD;
             known to affect liver function.&#xD;
&#xD;
         14. Have previously completed or withdrawn from this study investigating GB1211, and have&#xD;
             previously received the investigational product.&#xD;
&#xD;
         15. Subject who, in the opinion of the Investigator (or designee), should not participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ashley Brooks, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Bertil Lindmark MD PHD, Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Galecto Biotech AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>(For Parts A and B) Covance Clinical Research Unit Ltd</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <results_first_submitted>December 18, 2020</results_first_submitted>
  <results_first_submitted_qc>February 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GB1211</keyword>
  <keyword>Phase 1</keyword>
  <keyword>First Time in Human</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Single Ascending Dose (SAD)</keyword>
  <keyword>Multiple Ascending Dose (MAD)</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Nonalcoholic Steatohepatitis (NASH)</keyword>
  <keyword>Liver Fibrosis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03809052/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03809052/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 78 subjects entered the study and were randomised to treatment, with 56 subjects in Part A and 22 subjects in Part B.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>A1 - 5 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P2">
          <title>A2 - 20 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P3">
          <title>A3 - 50 mg GB1211 Single Dose (Food Effect Cohort)</title>
          <description>6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P4">
          <title>A4 - 100 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P5">
          <title>A5 - 200 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P6">
          <title>A6 - 50mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P7">
          <title>A7 - 400 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 400 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P8">
          <title>Part A - Placebo GB1211</title>
          <description>In Part A, 14 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use</description>
        </group>
        <group group_id="P9">
          <title>B1 - GB1211 Multiple Ascending Doses, 50mg BID</title>
          <description>GB1211 50 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P10">
          <title>B2 - GB1211 Multiple Ascending Doses, 100mg BID</title>
          <description>GB1211 100 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="P11">
          <title>Part B - PLacebo GB1211 (BID)</title>
          <description>In Part B, 6 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A1 - 5 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B2">
          <title>A2 - 20 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B3">
          <title>A3 - 50 mg GB1211 Single Dose (Food Effect Cohort)</title>
          <description>6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B4">
          <title>A4 - 100 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B5">
          <title>A5 - 200 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B6">
          <title>A6 - 50mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B7">
          <title>A7 - 400 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 400 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B8">
          <title>Part A - Placebo for GB1211</title>
          <description>In Part A, 14 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use Placebo: Hard capsules for oral use</description>
        </group>
        <group group_id="B9">
          <title>B1 - GB1211 Multiple Ascending Doses, 50mg BID</title>
          <description>GB1211 50mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B10">
          <title>B2 - GB1211 Multiple Ascending Doses, 100mg BID</title>
          <description>GB1211 100mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="B11">
          <title>Part B - Placebo for GB1211 (BID)</title>
          <description>In Part B, 6 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use&#xD;
Placebo: Hard capsules for oral use</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="14"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="7.4"/>
                    <measurement group_id="B2" value="38" spread="12.8"/>
                    <measurement group_id="B3" value="28" spread="8.0"/>
                    <measurement group_id="B4" value="35" spread="9.2"/>
                    <measurement group_id="B5" value="36" spread="12.8"/>
                    <measurement group_id="B6" value="34" spread="13.5"/>
                    <measurement group_id="B7" value="39" spread="11.3"/>
                    <measurement group_id="B8" value="37" spread="13.3"/>
                    <measurement group_id="B9" value="42" spread="12.6"/>
                    <measurement group_id="B10" value="37" spread="11.6"/>
                    <measurement group_id="B11" value="39" spread="8.1"/>
                    <measurement group_id="B12" value="36" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.9" spread="7.27"/>
                    <measurement group_id="B2" value="77.9" spread="19.03"/>
                    <measurement group_id="B3" value="71.4" spread="7.87"/>
                    <measurement group_id="B4" value="75.1" spread="13.94"/>
                    <measurement group_id="B5" value="73.7" spread="11.61"/>
                    <measurement group_id="B6" value="73.3" spread="16.72"/>
                    <measurement group_id="B7" value="79.7" spread="12.63"/>
                    <measurement group_id="B8" value="81.3" spread="12.82"/>
                    <measurement group_id="B9" value="85.4" spread="17.20"/>
                    <measurement group_id="B10" value="76.8" spread="9.52"/>
                    <measurement group_id="B11" value="70.9" spread="13.24"/>
                    <measurement group_id="B12" value="76.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.3" spread="10.31"/>
                    <measurement group_id="B2" value="171.7" spread="9.65"/>
                    <measurement group_id="B3" value="169.8" spread="5.00"/>
                    <measurement group_id="B4" value="175.3" spread="5.20"/>
                    <measurement group_id="B5" value="174.7" spread="8.45"/>
                    <measurement group_id="B6" value="176.2" spread="12.86"/>
                    <measurement group_id="B7" value="173.7" spread="8.12"/>
                    <measurement group_id="B8" value="173.6" spread="10.26"/>
                    <measurement group_id="B9" value="178.9" spread="7.62"/>
                    <measurement group_id="B10" value="173.4" spread="4.21"/>
                    <measurement group_id="B11" value="175.2" spread="5.71"/>
                    <measurement group_id="B12" value="174.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="4.48"/>
                    <measurement group_id="B2" value="26.1" spread="3.91"/>
                    <measurement group_id="B3" value="24.8" spread="2.73"/>
                    <measurement group_id="B4" value="24.5" spread="4.63"/>
                    <measurement group_id="B5" value="24.1" spread="3.25"/>
                    <measurement group_id="B6" value="23.3" spread="2.86"/>
                    <measurement group_id="B7" value="26.2" spread="1.90"/>
                    <measurement group_id="B8" value="26.9" spread="3.06"/>
                    <measurement group_id="B9" value="26.5" spread="3.78"/>
                    <measurement group_id="B10" value="25.5" spread="2.35"/>
                    <measurement group_id="B11" value="23.0" spread="3.50"/>
                    <measurement group_id="B12" value="25.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With of Adverse Events (AEs)</title>
        <description>The number of participants in each arm that report Adverse Events (AEs)</description>
        <time_frame>Up to 5-7 days post final dose (Part A: Single dose), Part B: 6-7 weeks</time_frame>
        <population>All subjects in part A and B were included in the safety populations. The safety population will include all subjects who received at least 1 dose of study treatment (GB1211 or placebo). Safety parameters will be listed and summarised using descriptive statistics. No formal statistical analysis of safety data is planned.</population>
        <group_list>
          <group group_id="O1">
            <title>A1 - 5 mg GB1211 Single Dose</title>
            <description>6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O2">
            <title>A2 - 20 mg GB1211 Single Dose</title>
            <description>6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O3">
            <title>A3 - 50 mg GB1211 Single Dose (Food Effect Cohort)</title>
            <description>6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O4">
            <title>A4 - 100 mg GB1211 Single Dose</title>
            <description>6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O5">
            <title>A5 - 200 mg GB1211 Single Dose</title>
            <description>6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O6">
            <title>A6 - 50mg GB1211 Single Dose</title>
            <description>6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O7">
            <title>A7 - 400 mg GB1211 Single Dose</title>
            <description>6 healthy subjects are administered 400 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O8">
            <title>Part A - Placebo for GB1211</title>
            <description>In Part A, 14 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use</description>
          </group>
          <group group_id="O9">
            <title>B1 - GB1211 Multiple Ascending Doses, 50mg BID</title>
            <description>GB1211 50 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O10">
            <title>B2 - GB1211 Multiple Ascending Doses, 100mg BID</title>
            <description>GB1211 100 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
          </group>
          <group group_id="O11">
            <title>Part B - Placebo for GB1211 (BID)</title>
            <description>In Part B, 6 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With of Adverse Events (AEs)</title>
          <description>The number of participants in each arm that report Adverse Events (AEs)</description>
          <population>All subjects in part A and B were included in the safety populations. The safety population will include all subjects who received at least 1 dose of study treatment (GB1211 or placebo). Safety parameters will be listed and summarised using descriptive statistics. No formal statistical analysis of safety data is planned.</population>
          <units>Count of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5-7 days post final dose (Part A: Single dose), Part B: 6-7 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A - Placebo for GB1211</title>
          <description>In Part A, 14 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use</description>
        </group>
        <group group_id="E2">
          <title>Part A - Placebo GB1211 (Fed)</title>
          <description>In Part A, 2 subjects will receive placebo in total in a fed state.&#xD;
Placebo: Hard capsules for oral use</description>
        </group>
        <group group_id="E3">
          <title>A1 - 5 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E4">
          <title>A2 - 20 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E5">
          <title>A3 - 50 mg GB1211 Single Dose (Period 1: Fasted)&quot; and &quot;A3- 50 mg GB1211 Single Dose (Period 2: Fed)</title>
          <description>6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E6">
          <title>A6 - 50mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E7">
          <title>A3- 50 mg GB1211 Single Dose (Fed)</title>
          <description>6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E8">
          <title>A4 - 100 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E9">
          <title>A5 - 200 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E10">
          <title>A7 - 400 mg GB1211 Single Dose</title>
          <description>6 healthy subjects are administered 400 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E11">
          <title>Part B - Placebo for GB1211 (BID)</title>
          <description>In Part B, 6 subjects will receive placebo in total.&#xD;
Placebo: Hard capsules for oral use</description>
        </group>
        <group group_id="E12">
          <title>B1 - GB1211 Multiple Ascending Doses, 50mg BID</title>
          <description>GB1211 50 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
        <group group_id="E13">
          <title>B2 - GB1211 Multiple Ascending Doses, 100mg BID</title>
          <description>GB1211 100mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.&#xD;
GB1211: Hard capsules for oral use</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>TEAEs reported at Part B Placebo group (1AE) and Part B B1 100mg BID group (2AEs) were determined to be drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>The TEAE was determined to be drug-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>The TEAE was determined to be drug-related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>The TEAE was determined to be drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>The TEAE was determined to be drug-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>The TEAE was determined to be drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <description>The TEAE was determined to be drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>The TEAE was determined to be drug-related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>The TEAE reported at Part A Placebo group was determined to be drug related. The TEAE reported on 3 subjects from Part B B1 50mg BID group were determined to be drug related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <description>The TEAE reported to 2 subjects was determined to be tdrug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <description>the TEAE was determined to be drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <description>the TEAE was determined to be drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>The TEAE was determined to be drug related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Bertil Lindmark, Chief Medical Officer</name_or_title>
      <organization>Galecto BIotech</organization>
      <phone>+45 70 70 52 10</phone>
      <email>info@galecto.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

